Joshua Willey, MD
Neurology · New York, NYNPI 1073667101
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,310 of the $29,799 with a category attached, or 91.6%. Abbott accounts for 87.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $13,328 and has fallen 63.2% since, to $4,900 in 2025.
Across 41 payments — averaging $726.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$26K
- Briohealth Solutions, Inc.$4K
- Irhythm Technologies, Inc.$36
Across 20 payments — averaging $7195.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$59K
- AbbVie$43K
- E.r. Squibb & Sons, L.L.C.$42K
What the payments were for
- Consulting fees$27,31092%
- Travel & lodging$2,3368%
- Food & beverage$1521%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 35 | $26,088 |
| Briohealth Solutions, Inc. | 5 | $3,675 |
| Irhythm Technologies, Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$18,968
- HeartMate 3 Left Ventricular Assist Device$4,948
- BRIOVAD$3,675
- HeartMate$1,950
- CARDIOMEMS$201
How this compares
$29,799 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $16,843 |
| Verapamil SrVerapamil Hcl | 12 | $1,183 |
| Levetiracetam | 15 | $933 |
| Lacosamide | 12 | $656 |
| Pregabalin | 29 | $467 |
| Gabapentin | 19 | $402 |
| Rosuvastatin Calcium | 24 | $383 |
| Atorvastatin Calcium | 23 | $364 |
| ClopidogrelClopidogrel Bisulfate | 19 | $310 |
| Duloxetine Hcl | 20 | $201 |
Paid to pharmacies, not to this prescriber.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- Steven WolfNew York$428K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.